miR-196a在非小细胞肺癌中的表达及临床意义  

Expression of miR-196a in non-small cell lung cancer and its clinical significance

作　　者：章海燕[1] 刘连科[2] 束永前[2] 杨丰名 

机构地区：[1]沭阳县人民医院肿瘤血液科,江苏沭阳223600 [2]南京医科大学第一附属医院肿瘤科,江苏南京210029

出　　处：《中国临床研究》2016年第10期1330-1332,共3页Chinese Journal of Clinical Research

基　　金：国家自然科学基金资助(81272532)

摘　　要：目的探讨微小核糖核酸-196a(microRNA-196a,miR-196a)在非小细胞肺癌(NSCLC)中的表达水平及其相应临床意义。方法从44例NSCLC组织及其相应癌旁组织中提取总RNA,并使用实时荧光定量聚合酶链反应(qRT-PCR)技术检测miR-196a的相对表达量,分析NSCLC患者临床TNM分期及无病生存期(DFS)与miR-196a表达水平之间的关系。结果 miR-196a在86.36%(38/44)的NSCLC组织中相对高表达;临床分期Ⅲ期+Ⅳ期的NSCLC患者肿瘤组织中miR-196a的相对表达量(153.87±32.57)显著高于Ⅰ期(88.99±35.89)及Ⅱ期患者(96.37±46.53)的相对表达量(P均<0.01)。肿瘤组织中miR-196a高表达的NSCLC患者其中位DFS(15个月)显著短于miR-196a低表达患者(27个月,P<0.05)。结论 NSCLC组织中miR-196a高表达提示临床预后不佳,miR-196a有望作为NSCLC预后预测的分子标志物。Objective To investigate the expression level of micro ribonucleic acid（ microRNA-196 a,miR-196a） in nonsmall cell lung cancer（ NSCLC） and its clinical significance. Methods Total RNA was extracted from 44 cancer tissues and corresponding paracancerous tissues specimens of NSCLC. Real-time fluorescent quantitative polymerase chain reaction（ qRT-PCR） was used to detect the relative expression levels of miR-196 a. The association of clinical TNM staging and disease-free survival（ DFS） with miR-196 a expression were analyzed. Results A relative higher expression of miR-196 a presented in 86. 36%（ 38 /44） of NSCLC samples,and its expression level was significantly higher in NSCLC tissues of clinical stage Ⅲ and Ⅳ than those of stage Ⅰ and Ⅱ [（ 153. 87 ± 32. 57） vs（ 88. 99 ± 35. 89）,（ 153. 87 ± 32. 57） vs（ 96.37 ± 46. 53）,all P〈0. 01]. The median DFS of patients with miR-196 a high-expression in tumor tissues（ 15months） was significantly less than that of patients with miR-196 a low-expressionin tumor tissues（ 27 months,P〈0. 05）. Conclusion The high-expression level of miR-196 a in NSCLC tissues prompts the poor clinical prognosis,and miR-196 a is expected to serve as a molecular marker predicting the prognosis of NSCLC patients.

关 键 词：非小细胞肺癌 微小核糖核酸 微小核糖核酸-196a 肿瘤侵袭 TNM分期 无病生存期 

分 类 号：R734.2[医药卫生—肿瘤]